OBJECTIVE: Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc; scleroderma). The Patient-Reported Outcomes Measurement Information System (PROMIS) GI symptom item bank captures upper and lower GI symptoms (reflux, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating/flatulence, diarrhea, constipation, and fecal incontinence). The objective of this study was to evaluate the construct validity of the PROMIS GI bank in SSc. METHODS: A total of 167 patients with SSc were administered the PROMIS GI bank and the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (GIT 2.0) instrument. GIT 2.0 is a multi-item instrument that measures SSc-associated GI symptoms. Product-moment correlations and a multitrait-multimethod analysis of the PROMIS GI scales with the GIT 2.0 symptom scales were used to evaluate convergent and discriminant validity. RESULTS: Patients with SSc GI involvement had PROMIS GI scale scores 0.2-0.7 SD worse than the US general population. Correlations among scales measuring the same domains for the PROMIS GI and GIT 2.0 measures were large, ranging from 0.61 to 0.87 (average r = 0.77). The average correlation between different symptom scales was 0.22, supporting discriminant validity. CONCLUSION: This study provides support for the construct validity of the PROMIS GI scales in SSc. Future research is needed to assess the responsiveness to change of these scales in patients with SSc.
OBJECTIVE: Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc; scleroderma). The Patient-Reported Outcomes Measurement Information System (PROMIS) GI symptom item bank captures upper and lower GI symptoms (reflux, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating/flatulence, diarrhea, constipation, and fecal incontinence). The objective of this study was to evaluate the construct validity of the PROMIS GI bank in SSc. METHODS: A total of 167 patients with SSc were administered the PROMIS GI bank and the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (GIT 2.0) instrument. GIT 2.0 is a multi-item instrument that measures SSc-associated GI symptoms. Product-moment correlations and a multitrait-multimethod analysis of the PROMIS GI scales with the GIT 2.0 symptom scales were used to evaluate convergent and discriminant validity. RESULTS:Patients with SSc GI involvement had PROMIS GI scale scores 0.2-0.7 SD worse than the US general population. Correlations among scales measuring the same domains for the PROMIS GI and GIT 2.0 measures were large, ranging from 0.61 to 0.87 (average r = 0.77). The average correlation between different symptom scales was 0.22, supporting discriminant validity. CONCLUSION: This study provides support for the construct validity of the PROMIS GI scales in SSc. Future research is needed to assess the responsiveness to change of these scales in patients with SSc.
Authors: Bryce B Reeve; Ron D Hays; Jakob B Bjorner; Karon F Cook; Paul K Crane; Jeanne A Teresi; David Thissen; Dennis A Revicki; David J Weiss; Ronald K Hambleton; Honghu Liu; Richard Gershon; Steven P Reise; Jin-shei Lai; David Cella Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: Vijay Bodukam; Ron D Hays; Paul Maranian; Daniel E Furst; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Dinesh Khanna Journal: Rheumatology (Oxford) Date: 2010-09-30 Impact factor: 7.580
Authors: Brennan M R Spiegel; Ron D Hays; Roger Bolus; Gil Y Melmed; Lin Chang; Cynthia Whitman; Puja P Khanna; Sylvia H Paz; Tonya Hays; Steve Reise; Dinesh Khanna Journal: Am J Gastroenterol Date: 2014-09-09 Impact factor: 10.864
Authors: Christopher V Almario; William D Chey; Dinesh Khanna; Sasan Mosadeghi; Shahzad Ahmed; Elham Afghani; Cynthia Whitman; Garth Fuller; Mark Reid; Roger Bolus; Buddy Dennis; Rey Encarnacion; Bibiana Martinez; Jennifer Soares; Rushaba Modi; Nikhil Agarwal; Aaron Lee; Scott Kubomoto; Gobind Sharma; Sally Bolus; Brennan M R Spiegel Journal: Am J Gastroenterol Date: 2016-08-02 Impact factor: 10.864
Authors: Christopher V Almario; Megana L Ballal; William D Chey; Carl Nordstrom; Dinesh Khanna; Brennan M R Spiegel Journal: Am J Gastroenterol Date: 2018-10-15 Impact factor: 10.864
Authors: Christopher V Almario; William Chey; Aung Kaung; Cynthia Whitman; Garth Fuller; Mark Reid; Ken Nguyen; Roger Bolus; Buddy Dennis; Rey Encarnacion; Bibiana Martinez; Jennifer Talley; Rushaba Modi; Nikhil Agarwal; Aaron Lee; Scott Kubomoto; Gobind Sharma; Sally Bolus; Lin Chang; Brennan M R Spiegel Journal: Am J Gastroenterol Date: 2014-12-02 Impact factor: 10.864
Authors: John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna Journal: J Scleroderma Relat Disord Date: 2019-11-25
Authors: Susanna A Curtis; Amanda M Brandow; Michelle DeVeaux; Daniel Zeltermam; Lesley Devine; John D Roberts Journal: Cannabis Cannabinoid Res Date: 2020-09-02
Authors: Murray Baron; Bashar Kahaleh; Elana J Bernstein; Lorinda Chung; Philip J Clements; Christopher Denton; Robyn T Domsic; Nava Ferdowsi; Ivan Foeldvari; Tracy Frech; Jessica K Gordon; Marie Hudson; Sindhu R Johnson; Dinesh Khanna; Zsuzsannah McMahan; Peter A Merkel; Sonali Narain; Mandana Nikpour; John D Pauling; Laura Ross; Antonia Maria Valenzuela Vergara; Alessandra Vacca Journal: J Scleroderma Relat Disord Date: 2018-07-18